	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	343	amyloid adj fibril	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/11 16:03			0
2	BRS	L2	31591	immune adj response	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/11 16:02			0
3	BRS	L3	598	amyloid adj deposit	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/11 16:04			0
4	BRS	L4	13380	(immunoglobulin adj light adj chain) or (amyloid adj A adj protein) or (beta adj 2-microglobulin) or transthyretin or (cystatin adj C) or gelsolin or procalcitonin or (prp adj protein) or (amyloid adj beta-protein) or (apoA adj 1) or lysozyme	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/11 16:10			0
5	BRS	L5	3	(1 or 4) same 2 same 3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/11 16:10			0
6	BRS	L6	69606	adjuvant	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/11 16:14			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
7	BRS	L7	49421	freund or (bacilli adj calmette-guerin) or (corynebacterium adj parvum) or (aluminum adj hydroxide) or lysolecthin or (pluronic adj polyol) or polyanions or dinitrophenol	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/11 16:20			0
8	BRS	L8	14561	6 same 7	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/11 16:21			0
9	BRS	L9	2	composition same (1 or 4) same 8	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/11 16:22			0

=> d his

(FILE 'HOME' ENTERED AT 16:25:21 ON 11 JAN 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
16:25:48 ON 11 JAN 2003
L1 8496 S AMYLOID FIBRIL
L2 61313 S (IMMUNOGLOBULIN LIGHT CHAIN) OR (AMYLOID A PROTEIN) OR (BETA
L3 106972 S GELSOLIN OR PROCALCITONIN OR (PRP PROTEIN) OR (AMYLOID BETA-P
L4 172220 S L1 OR L2 OR L3
L5 9784 S AMYLOID DEPOSITS
L6 354436 S IMMUNE RESPONSE
L7 8 S L4 (P) L5 (P) L6
L8 3 DUPLICATE REMOVE L7 (5 DUPLICATES REMOVED)
L9 216993 S ADJUVANT
L10 0 S L8 (P) L9

=> log y

```
FILE 'HOME' ENTERED AT 16:25:21 ON [redacted] JAN 2003

=> file medline caplus biosis embase scisearch agricola
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:25:48 ON 11 JAN 2003

FILE 'CAPLUS' ENTERED AT 16:25:48 ON 11 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:25:48 ON 11 JAN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:25:48 ON 11 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:25:48 ON 11 JAN 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 16:25:48 ON 11 JAN 2003

=> s amyloid fibril
L1          8496 AMYLOID FIBRIL

=> s (immunoglobulin light chain) or (amyloid A protein) or (beta 2-microglobulin) or transthyreti
   4 FILES SEARCHED...
L2         61313 (IMMUNOGLOBULIN LIGHT CHAIN) OR (AMYLOID A PROTEIN) OR (BETA
                 2-MICROGLOBULIN) OR TRANSTHYRETIN OR (CYSTATIN C)

=> s gelsolin or procalcitonin or (prp protein) or (amyloid beta-protein) or (apoA 1) or lysozyme
   4 FILES SEARCHED...
L3        106972 GELSOLIN OR PROCALCITONIN OR (PRP PROTEIN) OR (AMYLOID BETA-PROT
                 EIN) OR (APOA 1) OR LYSOZYME

=> s l1 or l2 or l3
L4        172220 L1 OR L2 OR L3

=> s amyloid deposits
L5          9784 AMYLOID DEPOSITS

=> s immune response
L6        354436 IMMUNE RESPONSE

=> s L4 (p) l5 (p) l6
L7             8 L4 (P) L5 (P) L6

=> duplicate remove l7
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L7
L8             3 DUPLICATE REMOVE L7 (5 DUPLICATES REMOVED)

=> d l8 1-3 ibib abs

L8   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         1999:753260  CAPLUS
DOCUMENT NUMBER:          131:350268
TITLE:                    Amyloid removal using anti-amyloid antibodies
INVENTOR(S):              Solomon, Alan; Hrncic, Rudi; Wall, Jonathan S.
PATENT ASSIGNEE(S):       The University of Tennessee Research Corporation, USA
SOURCE:                   PCT Int. Appl., 34 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9960024	A1	19991125	WO 1999-US11200	19990521
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2325600	AA	19991125	CA 1999-2325600	19990521
AU 9940075	A1	19991206	AU 1999-40075	19990521
EP 1078005	A1	20010228	EP 1999-923260	19990521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002515235	T2	20020528	JP 2000-549642	19990521

PRIORITY APPLN. INFO.: US 1998-86198P P 19980521
WO 1999-US11200 W 19990521

AB The authors disclose that the cell-mediated ***immune*** ***response*** to deposits of ***amyloid*** ***fibrils*** is enhanced by the opsonizing activity of anti-amyloid antibodies. In one example, ***amyloid*** ***deposits*** were shown to resolved in mice given anti-light chain antibodies; resoln. was myeloid cell (CD18)-dependent.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 92387806 MEDLINE
DOCUMENT NUMBER: 92387806 PubMed ID: 1516990
TITLE: Beta 2-microglobulin synthesis of mononuclear cells in chronic dialysis patients.
AUTHOR: Kumano K; Nanbu M; Kusakari S; Sakai T
CORPORATE SOURCE: Kidney Center, Kitasato University Hospital, Kanagawa, Japan.
SOURCE: INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, (1992 Jul) 15 (7) 401-7.
Journal code: 7802649. ISSN: 0391-3988.
PUB. COUNTRY: Italy
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199210
ENTRY DATE: Entered STN: 19921023
Last Updated on STN: 19921023
Entered Medline: 19921006

AB ***Beta*** ***2*** ***microglobulin*** (B2M) has been identified as a major component of ***amyloid*** ***deposits*** . This study was designed to determine whether changes occur in the synthesis of B2M in dialysis patients. Mononuclear cells (MNC) were isolated in peripheral blood from healthy volunteers, patients on hemodialysis (HD) and on continuous ambulatory peritoneal dialysis (CAPD). MNC were cultured in a medium of RPMI 1640 with or without interleukins IL-1, IL-2 or interferon INF-r. B2M in the cultured cells and supernatant was measured by enzyme immunoassay. IL-2 or INF-r stimulated B2M synthesis was significantly lower (25%) in patients on HD than in normal controls regardless of the type of dialysis membranes used, with no change in basal B2M synthesis. No differences were detected between healthy volunteers and CAPD patients. Preincubation of MNC with complement--activating or non-complement--activating membrane had no influence on B2M synthesis. The basal B2M synthesis of MNC significantly increased after a 4-hour HD regardless of the membranes used, and IL-2 and IFN-r stimulated synthesis were both essentially the same before and after HD. It was thus concluded that maximum capacity for B2M synthesis of MNC decreases in hemodialysis patients. This low responsiveness of MNC may be partially the cause for the reduction in cell-mediated ***immune*** ***response*** in HD patients.

L8 ANSWER 3 OF 3 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 84085526 MEDLINE

DOCUMENT NUMBER: 84085526 PubMed ID: 6360758
TITLE: Unanticipated a[redacted]idosis in dogs infused with i[redacted]lin.
AUTHOR: Albisser A M; McAdam K P; Perlman K; Carson S; B[redacted]oric A; Williamson J R
CONTRACT NUMBER: AM20579 (NIADDK)
HL13694 (NHLBI)
SOURCE: DIABETES, (1983 Dec) 32 (12) 1092-101.
Journal code: 0372763. ISSN: 0012-1797.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 198402
ENTRY DATE: Entered STN: 19900319
Last Updated on STN: 19970203
Entered Medline: 19840214

AB Highly purified regular porcine insulin was given by portable insulin pumps through indwelling vena caval catheters to 17 (13 normal, and 4 pancreatectomized) dogs initially weighing 15 +/- 2 kg at rates ranging from 2 to 10 mU/min (total 17-250 mg) over time periods ranging from 37 to 252 days. During the course of the study, many of the animals lost weight and became anemic. Since these conditions persisted and weight loss progressed even after cessation of insulin infusion, as many of the dogs as possible (15 of 17) were autopsied for microscopic studies. Large amounts of amyloid were demonstrated in the liver, kidney, spleen, and/or pancreas in 55% (6/11) of normal, and in 75% (3/4) of pancreatectomized dogs. The ***amyloid*** ***deposits*** were Congo red positive, exhibited classical apple green fluorescence under polarized light, and possessed the characteristic ultrastructural features of amyloid. Massive deposits of amyloid were observed in animals receiving as little as 17 mg of insulin over a time span of 52 days. In those animals with hepatic amyloid, marked hepatomegaly was present (i.e., 1200 +/- 250, X +/- SD, versus 300 +/- 25 g for normal animals) and preterminal serum alkaline phosphatase levels were markedly elevated (434 +/- 285 versus 30 +/- 14 IU/L for animals without hepatic amyloid). The magnitude of the hepatic ***amyloid*** ***deposits*** precludes the possibility that they represent insulin aggregates or insulin-derived products per se. No evidence of amyloid was present in any of the tissue biopsy specimens obtained prior to insulin infusion. Moreover, the possibility that this represents an ***immune*** ***response*** to the injected porcine insulin has to be viewed in light of the fact that the amino acid sequences of dog and porcine insulins are identical. It is of particular interest that the affinity of the ***amyloid*** ***deposits*** for Congo red stain was totally abolished by prior permanganate treatment, suggesting that the amyloid was derived from serum ***amyloid*** ***A*** ***protein*** rather than from ***immunoglobulin*** ***light*** ***chains*** or insulin aggregates per se. Further evidence that the protein was of the AA-type came from the initial biochemical characterization. Gel filtration on Sephadex G100 in 6 M guanidine hydrochloride identified two small molecular weight peaks of about 13,000 and 25,000 daltons, both of which inhibited the radioimmunoassay for human AA protein.(ABSTRACT TRUNCATED AT 400 WORDS)

=> d his

(FILE 'HOME' ENTERED AT 16:25:21 ON 11 JAN 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:25:48 ON 11 JAN 2003

L1 8496 S AMYLOID FIBRIL
L2 61313 S (IMMUNOGLOBULIN LIGHT CHAIN) OR (AMYLOID A PROTEIN) OR (BETA
L3 106972 S GELSOLIN OR PROCALCITONIN OR (PRP PROTEIN) OR (AMYLOID BETA-P
L4 172220 S L1 OR L2 OR L3
L5 9784 S AMYLOID DEPOSITS
L6 354436 S IMMUNE RESPONSE
L7 8 S L4 (P) L5 (P) L6
L8 3 DUPLICATE REMOVE L7 (5 DUPLICATES REMOVED)

=> s adjuvant
L9 216993 ADJUVANT

```
=> s l8 (p) l9
PROXIMITY OPERATOR LEVEL NOT CONSIS[redacted]T WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L62 (P) L53'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L64 (P) L54'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L66 (P) L55'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L68 (P) L56'
L10           0 L8 (P) L9

=> d his

     (FILE 'HOME' ENTERED AT 16:25:21 ON 11 JAN 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     16:25:48 ON 11 JAN 2003
L1          8496 S AMYLOID FIBRIL
L2         61313 S (IMMUNOGLOBULIN LIGHT CHAIN) OR (AMYLOID A PROTEIN) OR (BETA
L3        106972 S GELSOLIN OR PROCALCITONIN OR (PRP PROTEIN) OR (AMYLOID BETA-P
L4        172220 S L1 OR L2 OR L3
L5          9784 S AMYLOID DEPOSITS
L6        354436 S IMMUNE RESPONSE
L7             8 S L4 (P) L5 (P) L6
L8             3 DUPLICATE REMOVE L7 (5 DUPLICATES REMOVED)
L9        216993 S ADJUVANT
L10            0 S L8 (P) L9

=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY    SESSION
FULL ESTIMATED COST                               60.05      60.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                  ENTRY    SESSION
CA SUBSCRIBER PRICE                               -0.65      -0.65

STN INTERNATIONAL LOGOFF AT 16:31:47 ON 11 JAN 2003
```